Postoperative Crizotinib Fails in Early Lung Cancer

By News Health
6 hours Ago

(MedPage Today) — Adjuvant crizotinib (Xalkori) failed to improve disease-free survival (DFS) in patients with surgically resected early-stage ALK-positive non-small cell lung cancer (NSCLC), the phase III ECOG-ACRIN E4512 trial showed.
Among…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117362

Author :

Publish date : 2025-09-08 18:52:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Large Jump in Poison Center Calls Tied to Self-Harm in Preteens

Another Man Gets a Pig Kidney as Transplant Trials Are Poised to Start

Alzheimer's Disease Exacerbated by Air Pollution, Autopsy Study Suggests

BMI Proves Reliable for Youth Adiposity Detection

NIH Chief Becomes Loomer's Next Target

Later Breakfast Tied to Morbidity, Mortality in Older Adults